europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

2016: First curative gene therapy for ADA-SCID approved for infants

18/06/2021

Nominated by: Federchimica Assobiotec

Organisation in nomination: GlaxoSmithKline (GSK), currently moved to Orchard Therapeutics, Telethon Foundation (Telethon), l’IRCCS San Raffaele Hospital (SRH) Italy and Molecular Medicine SpA now AGC Biologics, Italy

       

Adenosine deaminase severe combined immunodeficiency (ADA-SCID) is a rare, inherited, paediatric disorder that can be fatal if untreated.  Patients will usually be diagnosed by the age of 5 months, with a life expectancy of less than 2 years without early detection and effective treatment.  It occurs in between approx. one in 200,000 to one in 1,000,000 newborns globally.

2016 saw the first approval for a gene therapy that uses the patient’s own stem cells with the gene modified to correct the disease at its root. It allows children to acquire a functioning immune system and eliminate the genetic error with which they were born that causes adenosine-deaminase enzyme deficiency.

From 2000 to present – considering clinical trial participants, compassionate use access and post marketing authorization (AIC) access, 40 patients with gene therapy have been successfully treated with gene therapy for this rare and serious immune disease.

The EMA reviewed data both in patients treated and on the other therapies available for this pathology to consider balance between risk and benefits after 5 years.  In 2021, it expressed favourable opinion on the maintenance of this gene therapy on the market for the administration of the drug in patients with ADA-SCID without a compatible donor.

References:

  • Strimvelis, Common name: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Assessment report, 2016
  • Strimvelis ® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies